Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

References

• Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Gangatharan S, Kuruvilla J. Relapsed and refractory aggressive NHL: Time for a change. Transfus Apher Sci 2013;49:72–79.
   PubMed Web of Science ®Google Scholar
• Baumgarten A, Finke J, Marks R. Aktuelle Diagnostik und Therapie bei B-zell non Hodgkin Lymphomen. Ther Umsch 2012;69:571–575.
   PubMedGoogle Scholar
• Gisselbrecht C, Glass B, Mounier N, Gill DS, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab Era. J Clin Oncol 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Brit J Haematol 2008;143:607–621.
   PubMed Web of Science ®Google Scholar
• Badin F, Hayslip J. Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness. Clinicoecon Outcomes Res 2010;2:37–45.
   PubMedGoogle Scholar
• Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406–413.
   PubMed Web of Science ®Google Scholar
• Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: Implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk 2010;10:192–196.
   PubMed Web of Science ®Google Scholar
• Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: An intention to mobilize and transplant analysis. Eur J Haematol 2004;72:10–17.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Tabacof J, Shen ZX, Jäger U. Aggressive non-Hodgkin's lymphoma—long-term survival for all patients? Hematol Meeting Rep 2007;1:27–41.
   Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program 2011;2011:498–505.
   PubMed Web of Science ®Google Scholar
• Martelli M, Ferreri AJM, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013;87:146–171.
   PubMed Web of Science ®Google Scholar
• Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995;13:588–595.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Engert A, Schulz H. Expanded use of rituximab in the management of non-Hodgkin lymphoma. Onco Targets Ther 2009;2:189–197.
   PubMed Web of Science ®Google Scholar
• Sud R, Friedberg JW. Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma–Impact of prior rituximab. Haematologica 2008;93:1776–1780.
   PubMed Web of Science ®Google Scholar
• Dotan E, Aggarwal C, Smith MR. Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin's lymphoma. P T 2010;35:148–157.
   PubMedGoogle Scholar
• Mey UJM, Olivieri A, Orlopp KS, Rabe C, Strehl JW, Gorschlueter M, et al. DHAP in combination with rituximab vs. DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: A matched-pair analysis. Leuk Lymphoma 2006;47:2558–2566.
   PubMed Web of Science ®Google Scholar
• Mey UJM, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest 2006;24:593–600.
   PubMed Web of Science ®Google Scholar
• Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a multicenter phase II study. Ann Oncol 2005;16:1359–1365.
   PubMed Web of Science ®Google Scholar
• Li YH, Jiang WQ, Huang HQ, Zhang L, Liu DG, Xu RH, et al. Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma. Ai Zheng 2002;21:900–902.
   PubMedGoogle Scholar
• Olivieri A, Offidani M, Ciniero L, Cantori I, Ombrosi L, Mancini S, et al. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplant 1995;16:85–89.
   PubMed Web of Science ®Google Scholar
• PhilipT, Chauvin F, Bron D, Guglielmi C, Hagenbeek A, Coiffier B, et al. PARMA international protocol:Pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). Ann Oncol 1991;2:57–64.
   PubMed Web of Science ®Google Scholar
• Press OW, Livingston R, Mortimer J, Collins C, Appelbaum F. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 1991;9:423–431.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117–122.
   PubMed Web of Science ®Google Scholar
• Jermann M, Jost LM, Taverna CH, Jacky E, Honegger HP, Betticher DC, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: Results of a phase II study. Ann Oncol 2004;15:511–516.
   PubMed Web of Science ®Google Scholar
• Vellenga E, van Putten WLJ, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MHJ, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL:A prospective randomized HOVON trial. Blood 2008;111:537–43.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz D, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684–3688.
   PubMed Web of Science ®Google Scholar
• Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome. A GEL/TAMO study.Haematologica 2008;93:1829–1836.
   Web of Science ®Google Scholar
• Borgerding A, Hasenkamp J, Glaß B, Wulf G, Trümper L. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Ann Hematol 2010;89:283–289.
   PubMed Web of Science ®Google Scholar
• Redondo AM, Pomares H, Vidal MJ, Pascual MJ, Quereda B, Sancho JM, et al. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: A multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. Br J Haematol 2014;164:668–674.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Briere J, Mounier N, Voelker H-U, Cuccuini W, Hirchaud E, et al. The germinal center/activated b-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A Bio-CORAL study. J Clin Oncol 2011;29:4079–4087.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma:A phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma 2008;49:1074–1080.
   PubMed Web of Science ®Google Scholar
• Lignon J, Sibon D, Madelaine I, Brice P, Franchi P, Briere J, et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010;10:262–269.
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014;32:3490–3496.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Chauvin F, Hagenbeek A, van der Lely J, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Sieniawski M, Staak O, Glossmann JP, Reineke T, Scheuss H, Diehl V, et al. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Hematol 2007;86:107–115.
   PubMed Web of Science ®Google Scholar